Weight-loss medications have changed how millions of people think about obesity, appetite and long-term weight management. Medicines such as Ozempic, Wegovy and Mounjaro can help people lose substantial amounts of weight, but an important question often emerges after the initial success: what happens when you stop taking them?
For some people, the months following their final dose bring back hunger, gradual weight regain and the return of old eating patterns. Others may maintain some of their weight loss, particularly when they have additional medical support and sustainable lifestyle changes in place.
The science is becoming clearer: these medications do not simply remove excess weight and permanently switch off the biological processes that contributed to it. They influence appetite, fullness, blood sugar regulation and other metabolic signals. When treatment ends, some of those effects diminish.
Understanding what happens next is essential for anyone considering these medicines—not just for losing weight, but for managing their health over the long term.
How Ozempic, Wegovy and Mounjaro work inside the body
Although these medicines are often discussed together, they are not identical.
-
Ozempic contains semaglutide and is primarily prescribed to treat type 2 diabetes in the United States. It can also lead to significant weight loss.
-
Wegovy also contains semaglutide, but is approved for chronic weight management in eligible patients and has specific indications that vary by country.
-
Mounjaro contains tirzepatide, which acts on two hormone receptors involved in blood sugar regulation and appetite. Its approved uses vary by country; in the United States, tirzepatide is marketed for weight management under the brand Zepbound.
These medicines influence pathways involving GLP-1, a hormone associated with appetite, digestion and glucose regulation. Tirzepatide also activates the GIP receptor.
The result can be reduced hunger, increased feelings of fullness and lower food intake. They can also help regulate blood glucose in people with diabetes.
Image suggestion: How gut hormones communicate with the brain to influence appetite and fullness.
The important distinction is that these medicines help regulate biological processes while they are being taken. They do not guarantee that the body’s appetite signals, energy balance or tendency to regain weight will remain unchanged after treatment ends.
What happens when you stop taking weight-loss injections?
There is no single experience shared by everyone. The timing and degree of change depend on the medication, dose, duration of treatment, individual biology, other health conditions and lifestyle.
1. Hunger may gradually return
One of the earliest changes some people notice is an increase in appetite.
While taking a GLP-1 medicine, a person may feel satisfied with smaller meals or find that persistent thoughts about food become less intrusive. After stopping, these effects can diminish as the medicine leaves the body.
Food may become more appealing again, portion sizes may increase, and the interval between meals may feel harder to manage.
This is not necessarily a failure of discipline. Appetite is regulated by a complex network of hormonal, neurological and environmental signals. Obesity can involve biological mechanisms that make maintaining weight loss difficult.
2. Weight regain may begin over the following weeks and months
Weight does not necessarily return immediately after the final injection. Instead, changes can accumulate over time as appetite increases and the medication’s effects fade.
A major question is how much of the lost weight people regain—and how quickly.
A systematic review published in The BMJ in January 2026 examined 37 studies involving 9,341 adults who stopped weight-management medicines. Across the included treatments, weight increased by an average of approximately 0.4 kilograms per month after discontinuation. Estimates for newer medicines, including semaglutide and tirzepatide, suggested faster regain, averaging around 0.8 kilograms per month. These are pooled averages, not predictions for an individual patient.
The takeaway is not that everyone will regain all their weight. It is that weight regain is common enough to be an important part of the treatment plan before medication is discontinued.
What clinical trials reveal about stopping treatment
The strongest evidence comes from studies that followed people after switching from active treatment to a placebo.
The semaglutide findings
In the STEP 1 trial extension, researchers followed a subset of adults who had taken semaglutide 2.4 mg weekly alongside lifestyle support.
Participants lost an average of 17.3% of their starting body weight during 68 weeks of treatment. During the following year, after both semaglutide and the structured lifestyle intervention were withdrawn, they regained an average of 11.6 percentage points of their original body weight.
In practical terms, they regained roughly two-thirds of the weight they had lost. On average, they still weighed 5.6% less than at the start of the study after the additional year.
The tirzepatide findings
The SURMOUNT-4 clinical trial examined what happened when people who had initially lost weight on tirzepatide either continued treatment or switched to a placebo.
After an initial 36-week treatment period, participants had lost an average of 20.9% of their body weight. Over the next 52 weeks, those who switched to placebo regained an average of 14.0% of their body weight from the point of switching, while those who continued tirzepatide lost a further 5.5% on average.
Image suggestion: Researchers studying long-term weight changes after obesity medication withdrawal.
These trials provide an important message: the benefits of treatment may not persist to the same degree once the medication is stopped. However, neither study proves that every person will regain the same amount of weight, and the results should not be used to predict an individual’s outcome.
Does stopping Ozempic, Wegovy or Mounjaro affect blood sugar?
For people taking these medicines to manage type 2 diabetes, the consequences can extend beyond body weight.
Semaglutide and tirzepatide help regulate blood glucose. When treatment stops, that benefit can diminish, potentially causing blood sugar levels to rise again.
The degree of change depends on factors such as pancreatic function, the severity of diabetes, other medications and changes in diet or physical activity.
Someone who has been using Ozempic or Mounjaro for diabetes should therefore discuss a treatment transition with their clinician before stopping. A replacement medicine or adjustment to an existing regimen may be necessary.
Weight regain can also affect blood pressure, blood lipids and other metabolic measures. In the semaglutide withdrawal study, several improvements in cardiometabolic risk factors moved back towards their starting levels during follow-up.
This is why weight management should be evaluated through more than the number on the scale. Blood glucose, cardiovascular risk, mobility and overall health matter too.
What about side effects after stopping?
Many common side effects of GLP-1 medicines involve the digestive system. These can include nausea, vomiting, diarrhoea, constipation and abdominal discomfort.
As the medication’s effects diminish, treatment-related digestive symptoms may improve. However, the timing varies, and stopping does not guarantee that every symptom will disappear immediately.
It is also important to distinguish medication side effects from symptoms caused by another medical condition. Persistent or severe abdominal pain, repeated vomiting or signs of dehydration warrant prompt medical assessment.
People should not stop or change a prescribed medicine solely because of information in an article. A healthcare professional can help determine whether symptoms require treatment, a dose adjustment or a change in medication.
Can you prevent weight regain after stopping weight-loss medication?
There is no guaranteed method that prevents weight regain after discontinuation. However, a planned transition can help people protect their health and maintain as much of their progress as possible.
Build a maintenance plan before the final dose
Rather than waiting until hunger returns, discuss the next stage of treatment with your healthcare professional in advance.
A practical plan may include:
-
Nutrition: Build meals around protein-rich foods, vegetables, fruit, whole grains and other sources of fibre. Individual protein needs vary, particularly for people with kidney disease or other medical conditions.
-
Physical activity: Combine regular movement with strength training appropriate to your abilities. Maintaining muscle is an important consideration during weight loss and weight maintenance.
-
Sleep and routine: Consistent sleep and regular meal patterns may help support appetite regulation and daily energy levels.
-
Monitoring: Track weight trends, appetite, blood pressure or glucose where appropriate, and any return of weight-related symptoms.
-
Follow-up care: Arrange regular appointments so that changes can be addressed early rather than after substantial weight regain.
Image suggestion: A balanced, nutrient-rich meal as part of a sustainable weight-maintenance strategy.
Is tapering the dose better than stopping abruptly?
Some patients wonder whether gradually reducing their injections will prevent the return of hunger or weight gain.
There is currently no universally established, evidence-based tapering schedule proven to prevent weight regain after stopping semaglutide or tirzepatide. A clinician may individualise a transition plan, but patients should not assume that tapering will eliminate the underlying biological tendency to regain weight.
For people with diabetes, the plan must also account for blood glucose control and any replacement treatment.
Do you have to take these medicines forever?
Not everyone will need the same treatment duration, and the answer depends on the medical reason for prescribing the medicine.
Obesity is often a chronic condition influenced by genetics, appetite regulation, environment and metabolism. For some patients, continued medication may be appropriate to maintain weight loss and related health benefits, provided the treatment remains safe, effective and affordable.
Others may discontinue treatment because of side effects, personal preference, cost, pregnancy planning or a change in their medical circumstances.
The appropriate approach is an individual decision made with a qualified healthcare professional—not a universal rule that everyone must continue indefinitely or that everyone should stop once a target weight is reached.
The financial question: what if you cannot afford the medication?
Cost is a significant consideration for people who depend on long-term treatment. If injections become unaffordable, the resulting interruption can be particularly difficult when appetite returns and weight begins to increase.
Before treatment starts, patients should ask their clinician about the expected duration of therapy, the total cost, alternatives and what to do if they can no longer pay for it.
Depending on the individual’s diagnosis and country, alternatives may include other approved weight-management medicines, structured lifestyle programmes, dietetic support or other evidence-based obesity treatments.
Not every alternative produces the same results, and medicines prescribed for diabetes are not automatically interchangeable with those approved specifically for weight management. Patients should also avoid unverified online products and counterfeit injections.
What researchers still need to understand
Image suggestion: Ongoing research into metabolism, obesity and the long-term effects of treatment.
Although clinical trials have established that weight regain is common after GLP-1-based medicines are withdrawn, important questions remain.
Researchers need better evidence on which patients are most likely to maintain their weight loss, whether specific transition strategies are effective, how long-term treatment affects different populations, and how to balance clinical benefits against costs and side effects.
Another important question is whether people who discontinue medication can retain meaningful health improvements even if some weight returns. Weight is only one measure of health, and an individual’s outcome cannot be judged by weight alone.
Future research may also clarify how medication, behavioural support and other treatments can be combined to make long-term weight management more sustainable.
The bottom line: stopping the drug does not end the biology of obesity
Ozempic, Wegovy and Mounjaro can help eligible patients achieve substantial weight loss, but the effects of treatment do not necessarily remain unchanged after the medication is withdrawn.
Hunger may return, weight regain is common, and improvements in blood glucose and other metabolic risk factors may diminish. At the same time, individual outcomes vary, and some people retain part or much of their weight loss.
The most important conversation is not simply whether someone should stop taking a weight-loss injection. It is what happens next.
For anyone considering treatment, the goal should be a medically appropriate, financially realistic and sustainable approach to long-term health—with a plan for maintenance or alternative treatment if the medication is discontinued.
Medical disclaimer: This article is for educational purposes only and is not a substitute for individual medical advice. Consult a qualified healthcare professional before starting, stopping or changing a prescription medicine.
